TherapeuticsMD, Inc.
TXMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 35.3% | -98.1% | 2,619.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 98% | 45.5% |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -169.4% | -620.9% | 17% | -2,753.2% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -123.9% | -789.4% | 160.1% | -6,700.9% |
| EPS Diluted | -0.19 | -0.74 | -10.35 | -25.83 |
| % Growth | 74.3% | 92.9% | 59.9% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | -$0 |